Chronic Idiopathic Constipation Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL CHRONIC IDIOPATHIC CONSTIPATION DRUGS INDUSTRY

2.1 Summary about Chronic Idiopathic Constipation Drugs Industry

2.2 Chronic Idiopathic Constipation Drugs Market Trends

2.2.1 Chronic Idiopathic Constipation Drugs Production & Consumption Trends

2.2.2 Chronic Idiopathic Constipation Drugs Demand Structure Trends

2.3 Chronic Idiopathic Constipation Drugs Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Linaclotide 

4.2.2 Lubiprostone 

4.2.3 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital Pharmacies 

4.3.2 Retail Pharmacies 

4.3.3 Online Pharmacies

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Linaclotide 

5.2.2 Lubiprostone 

5.2.3 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital Pharmacies 

5.3.2 Retail Pharmacies 

5.3.3 Online Pharmacies

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Linaclotide 

6.2.2 Lubiprostone 

6.2.3 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital Pharmacies 

6.3.2 Retail Pharmacies 

6.3.3 Online Pharmacies

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Linaclotide 

7.2.2 Lubiprostone 

7.2.3 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital Pharmacies 

7.3.2 Retail Pharmacies 

7.3.3 Online Pharmacies

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Linaclotide 

8.2.2 Lubiprostone 

8.2.3 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital Pharmacies 

8.3.2 Retail Pharmacies 

8.3.3 Online Pharmacies

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Linaclotide 

9.2.2 Lubiprostone 

9.2.3 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital Pharmacies 

9.3.2 Retail Pharmacies 

9.3.3 Online Pharmacies

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Pfizer 

10.1.2 Glaxosmithkline 

10.1.3 Roche Holding AG 

10.1.4 Sanofi 

10.1.5 Bayer AG 

10.1.6 Merck 

10.1.7 Eli Lilly 

10.1.8 Allergens 

10.1.9 Chugai Pharmaceutical 

10.1.10 Ferring International Center S.A 

10.1.11 Synergy Pharmaceuticals 

10.1.12 Salix Pharmaceuticals Ltd 

10.1.13 Sucampo Pharmaceuticals Inc 

10.1.14 Ironwood Pharmaceuticals Inc 

10.1.15 Valeant Pharmaceuticals International 

10.1.16 Daiichi Sankyo 

10.1.17 Cosmo Pharmaceuticals SA 

10.1.18 Progenics Pharmaceuticals Inc 

10.1.19 Theravance Biopharma Inc

10.2 Chronic Idiopathic Constipation Drugs Sales Date of Major Players (2017-2020e)

10.2.1 Pfizer 

10.2.2 Glaxosmithkline 

10.2.3 Roche Holding AG 

10.2.4 Sanofi 

10.2.5 Bayer AG 

10.2.6 Merck 

10.2.7 Eli Lilly 

10.2.8 Allergens 

10.2.9 Chugai Pharmaceutical 

10.2.10 Ferring International Center S.A 

10.2.11 Synergy Pharmaceuticals 

10.2.12 Salix Pharmaceuticals Ltd 

10.2.13 Sucampo Pharmaceuticals Inc 

10.2.14 Ironwood Pharmaceuticals Inc 

10.2.15 Valeant Pharmaceuticals International 

10.2.16 Daiichi Sankyo 

10.2.17 Cosmo Pharmaceuticals SA 

10.2.18 Progenics Pharmaceuticals Inc 

10.2.19 Theravance Biopharma Inc

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Chronic Idiopathic Constipation Drugs Product Type Overview

Table Chronic Idiopathic Constipation Drugs Product Type Market Share List

Table Chronic Idiopathic Constipation Drugs Product Type of Major Players

Table Brief Introduction of Pfizer 

Table Brief Introduction of Glaxosmithkline 

Table Brief Introduction of Roche Holding AG 

Table Brief Introduction of Sanofi 

Table Brief Introduction of Bayer AG 

Table Brief Introduction of Merck 

Table Brief Introduction of Eli Lilly 

Table Brief Introduction of Allergens 

Table Brief Introduction of Chugai Pharmaceutical 

Table Brief Introduction of Ferring International Center S.A 

Table Brief Introduction of Synergy Pharmaceuticals 

Table Brief Introduction of Salix Pharmaceuticals Ltd 

Table Brief Introduction of Sucampo Pharmaceuticals Inc 

Table Brief Introduction of Ironwood Pharmaceuticals Inc 

Table Brief Introduction of Valeant Pharmaceuticals International 

Table Brief Introduction of Daiichi Sankyo 

Table Brief Introduction of Cosmo Pharmaceuticals SA 

Table Brief Introduction of Progenics Pharmaceuticals Inc 

Table Brief Introduction of Theravance Biopharma Inc

Table Products & Services of Pfizer 

Table Products & Services of Glaxosmithkline 

Table Products & Services of Roche Holding AG 

Table Products & Services of Sanofi 

Table Products & Services of Bayer AG 

Table Products & Services of Merck 

Table Products & Services of Eli Lilly 

Table Products & Services of Allergens 

Table Products & Services of Chugai Pharmaceutical 

Table Products & Services of Ferring International Center S.A 

Table Products & Services of Synergy Pharmaceuticals 

Table Products & Services of Salix Pharmaceuticals Ltd 

Table Products & Services of Sucampo Pharmaceuticals Inc 

Table Products & Services of Ironwood Pharmaceuticals Inc 

Table Products & Services of Valeant Pharmaceuticals International 

Table Products & Services of Daiichi Sankyo 

Table Products & Services of Cosmo Pharmaceuticals SA 

Table Products & Services of Progenics Pharmaceuticals Inc 

Table Products & Services of Theravance Biopharma Inc

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Chronic Idiopathic Constipation Drugs Market Forecast (Million USD) by Region 2021f-2026f

Table Global Chronic Idiopathic Constipation Drugs Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Chronic Idiopathic Constipation Drugs Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Chronic Idiopathic Constipation Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f